AZNAstraZenecaRunning, no new patients
To Evaluate the Efficacy/Safety of Osimertinib Prior to CRT and Maintenance of it With Stage III, Unresectable NSCLC With EGFR Mutations
Lung Cancer
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 76 (final count)
- Started
- Apr 21, 2024
- Main results expected
- Jul 7, 2026
- Fully finished
- Jul 7, 2027
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
PFS (Progression-Free Survival)
Measured over: Assessed from date of first dose to progression (up to a maximum of approximately 4 years)
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06194448 · record last updated 2026-08-19 · checked 2026-11-09 15:47 UTC